Delayed
TEL AVIV STOCK EXCHANGE
13:49:49 12/05/2024 BST
|
5-day change
|
1st Jan Change
|
16.2
ILa
|
-1.82%
|
|
-1.22%
|
-2.99%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
301.1
|
374.5
|
483.5
|
1,454
|
224.2
|
195
|
Enterprise Value (EV)
1 |
292.4
|
380.2
|
472.6
|
1,387
|
182.6
|
180.2
|
P/E ratio
|
-16.1
x
|
-16.8
x
|
-22
x
|
-16.1
x
|
-5.79
x
|
-6.84
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-16
x
|
-18.4
x
|
-24.6
x
|
-36.8
x
|
-5.13
x
|
-6.41
x
|
EV / FCF
|
-41.7
x
|
-74.5
x
|
-55.4
x
|
-50.4
x
|
-8.92
x
|
-10.4
x
|
FCF Yield
|
-2.4%
|
-1.34%
|
-1.8%
|
-1.98%
|
-11.2%
|
-9.58%
|
Price to Book
|
-94.8
x
|
-27.3
x
|
15.8
x
|
17.2
x
|
3.98
x
|
6.66
x
|
Nbr of stocks (in thousands)
|
811,497
|
841,467
|
998,981
|
1,154,057
|
1,167,925
|
1,167,925
|
Reference price
2 |
0.3710
|
0.4450
|
0.4840
|
1.260
|
0.1920
|
0.1670
|
Announcement Date
|
30/03/19
|
31/03/20
|
26/03/21
|
31/03/22
|
30/03/23
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-18.25
|
-20.69
|
-19.23
|
-37.7
|
-35.6
|
-28.14
|
EBIT
1 |
-18.45
|
-20.91
|
-19.44
|
-38.14
|
-37.05
|
-29.79
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-18.74
|
-22.24
|
-22.02
|
-90.08
|
-38.7
|
-28.53
|
Net income
1 |
-18.74
|
-22.24
|
-22.02
|
-90.08
|
-38.7
|
-28.53
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0231
|
-0.0264
|
-0.0220
|
-0.0781
|
-0.0331
|
-0.0244
|
Free Cash Flow
1 |
-7.017
|
-5.104
|
-8.528
|
-27.53
|
-20.47
|
-17.26
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/19
|
31/03/20
|
26/03/21
|
31/03/22
|
30/03/23
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
5.77
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
8.64
|
-
|
10.9
|
67.2
|
41.7
|
14.8
|
Leverage (Debt/EBITDA)
|
-
|
-0.279
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-7.02
|
-5.1
|
-8.53
|
-27.5
|
-20.5
|
-17.3
|
ROE (net income / shareholders' equity)
|
392%
|
263%
|
-260%
|
-156%
|
-55%
|
-66.6%
|
ROA (Net income/ Total Assets)
|
-147%
|
-152%
|
-41.6%
|
-30.6%
|
-25.9%
|
-31.2%
|
Assets
1 |
12.78
|
14.59
|
52.94
|
294.3
|
149.5
|
91.55
|
Book Value Per Share
2 |
-0
|
-0.0200
|
0.0300
|
0.0700
|
0.0500
|
0.0300
|
Cash Flow per Share
2 |
0.0100
|
0
|
0.0200
|
0.0700
|
0.0500
|
0.0100
|
Capex
1 |
0.34
|
0.19
|
0.25
|
5.81
|
6.39
|
0.82
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/19
|
31/03/20
|
26/03/21
|
31/03/22
|
30/03/23
|
29/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -2.99% | 51.18M | | -10.15% | 1.16B | | -20.42% | 129M | | +2.15% | 74.76M | | +3.39% | 59.21M | | +5.05% | 57.19M |
Bio Medical Devices
|